Achieve Life Sciences, based in Seattle, is developing cytisinicline, a plant-based alkaloid, for smoking cessation and nicotine addiction, targeting cravings and withdrawal symptoms. The company employs 22 full-time staff.
Mark K Oki bought 10,000 shares of ACHV on 17 March at $2.89 per share, worth a total of $29K. They now own 10,000 ACHV shares.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
